Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBITDA (2020 - 2026)

Journey Medical filings provide 6 years of EBITDA readings, the most recent being $5.3 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 139.08% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.4 million, a 82.54% increase, with the full-year FY2025 number at -$2.4 million, up 82.54% from a year prior.
  • EBITDA hit $5.3 million in Q4 2025 for Journey Medical, up from -$1.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $17.2 million in Q3 2023 to a low of -$13.8 million in Q2 2021.
  • Median EBITDA over the past 5 years was -$3.1 million (2024), compared with a mean of -$4.0 million.
  • Biggest five-year swings in EBITDA: plummeted 5391.21% in 2021 and later surged 281.68% in 2023.
  • Journey Medical's EBITDA stood at -$9.1 million in 2021, then fell by 10.36% to -$10.0 million in 2022, then skyrocketed by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then surged by 139.08% to $5.3 million in 2025.
  • The last three reported values for EBITDA were $5.3 million (Q4 2025), -$1.5 million (Q3 2025), and -$2.9 million (Q2 2025) per Business Quant data.